1	6	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Angiogenesis	_	_	NN	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	Glioblastomas	_	_	NNP	_	_	_	_	_


1	Features	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	glioblastomas	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	high	_	_	JJ	_	_	_	_	_
7	propensity	_	_	NN	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	invade	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	surrounding	_	_	VBG	_	_	_	_	_
12	tissues	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	extensive	_	_	JJ	_	_	_	_	_
15	angiogenesis	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	characterized	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	pathological	_	_	JJ	_	_	_	_	_
7	vascular	_	_	JJ	_	_	_	_	_
8	system	_	_	NN	_	_	_	_	_
9	with	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	dense	_	_	JJ	_	_	_	_	_
12	network	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	winding	_	_	VBG	_	_	_	_	_
15	vessels	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	different	_	_	JJ	_	_	_	_	_
18	diameters	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	increased	_	_	VBN	_	_	_	_	_
21	permeability	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	abnormally	_	_	RB	_	_	_	_	_
26	thickened	_	_	VBN	_	_	_	_	_
27	basement	_	_	NN	_	_	_	_	_
28	membranes	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	properties	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	often	_	_	RB	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	cause	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	relapses	_	_	NNS	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	therapy	_	_	NN	_	_	_	_	_
11	failures	_	_	NNS	_	_	_	_	_
12	because	_	_	IN	_	_	_	_	_
13	they	_	_	PRP	_	_	_	_	_
14	hinder	_	_	VBP	_	_	_	_	_
15	tumor	_	_	NN	_	_	_	_	_
16	access	_	_	NN	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	cytotoxic	_	_	JJ	_	_	_	_	_
19	chemotherapy	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Angiogenesis	_	_	NN	_	_	_	_	_
2	caused	_	_	VBN	_	_	_	_	_
3	by	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	presence	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	tumor	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	defined	_	_	VBN	_	_	_	_	_
11	as	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	formation	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	new	_	_	JJ	_	_	_	_	_
16	blood	_	_	NN	_	_	_	_	_
17	vessels	_	_	NNS	_	_	_	_	_
18	based	_	_	VBN	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	existing	_	_	VBG	_	_	_	_	_
21	ones	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	which	_	_	WDT	_	_	_	_	_
24	can	_	_	MD	_	_	_	_	_
25	be	_	_	VB	_	_	_	_	_
26	visualized	_	_	VBN	_	_	_	_	_
27	using	_	_	VBG	_	_	_	_	_
28	ultra-high-field	_	_	JJ	_	_	_	_	_
29	magnetic	_	_	JJ	_	_	_	_	_
30	resonance	_	_	NN	_	_	_	_	_
31	angiography	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	mechanism	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	process	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	very	_	_	RB	_	_	_	_	_
8	complex	_	_	JJ	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	GBM	_	_	NNP	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	development	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	pathological	_	_	JJ	_	_	_	_	_
8	vasculature	_	_	NN	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	based	_	_	VBN	_	_	_	_	_
11	on	_	_	IN	_	_	_	_	_
12	changes	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	adhesion	_	_	NN	_	_	_	_	_
15	molecules	_	_	NNS	_	_	_	_	_
16	on	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	endothelial	_	_	JJ	_	_	_	_	_
19	surface	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	presence	_	_	NN	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	an	_	_	DT	_	_	_	_	_
25	erratic	_	_	JJ	_	_	_	_	_
26	basement	_	_	NN	_	_	_	_	_
27	membrane	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	a	_	_	DT	_	_	_	_	_
30	decrease	_	_	NN	_	_	_	_	_
31	in	_	_	IN	_	_	_	_	_
32	pericyte	_	_	NN	_	_	_	_	_
33	coverage	_	_	NN	_	_	_	_	_
34	,	_	_	,	_	_	_	_	_
35	and	_	_	CC	_	_	_	_	_
36	a	_	_	DT	_	_	_	_	_
37	weaker	_	_	JJR	_	_	_	_	_
38	binding	_	_	NN	_	_	_	_	_
39	of	_	_	IN	_	_	_	_	_
40	astrocytes	_	_	NNS	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	blood	_	_	NN	_	_	_	_	_
43	vessels	_	_	NNS	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	common	_	_	JJ	_	_	_	_	_
3	element	_	_	NN	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	large	_	_	JJ	_	_	_	_	_
7	invasiveness	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	angiogenesis	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	glioblastomas	_	_	NNS	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	loss	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	tumor	_	_	NN	_	_	_	_	_
17	cell	_	_	NN	_	_	_	_	_
18	boundaries	_	_	NNS	_	_	_	_	_
19	with	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	surrounding	_	_	VBG	_	_	_	_	_
22	microenvironment	_	_	NN	_	_	_	_	_
23	consisting	_	_	VBG	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	brain	_	_	NN	_	_	_	_	_
26	tissue	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	subarachnoid	_	_	JJ	_	_	_	_	_
29	space	_	_	NN	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	blood	_	_	NN	_	_	_	_	_
33	vessels	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Angiogenesis	_	_	NN	_	_	_	_	_
2	occurs	_	_	VBZ	_	_	_	_	_
3	under	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	influence	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	various	_	_	JJ	_	_	_	_	_
8	mechanisms	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	which	_	_	WDT	_	_	_	_	_
11	we	_	_	PRP	_	_	_	_	_
12	divide	_	_	VBP	_	_	_	_	_
13	into	_	_	IN	_	_	_	_	_
14	hypoxia-dependent	_	_	JJ	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	hypoxia-independent	_	_	JJ	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Hypoxia	_	_	NN	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	proven	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	inactivate	_	_	VB	_	_	_	_	_
7	prolyl	_	_	NN	_	_	_	_	_
8	hydroxylases	_	_	NNS	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	increases	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	level	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	hypoxia-inducible	_	_	JJ	_	_	_	_	_
7	factor-1α	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	HIF-1α	_	_	NN	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	causing	_	_	VBG	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	release	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	vascular	_	_	JJ	_	_	_	_	_
17	endothelial	_	_	JJ	_	_	_	_	_
18	growth	_	_	NN	_	_	_	_	_
19	factor	_	_	NN	_	_	_	_	_
20	(	_	_	-LRB-	_	_	_	_	_
21	VEGF	_	_	NN	_	_	_	_	_
22	)	_	_	-RRB-	_	_	_	_	_
23	by	_	_	IN	_	_	_	_	_
24	glioma	_	_	NN	_	_	_	_	_
25	cells	_	_	NNS	_	_	_	_	_
26	affected	_	_	VBN	_	_	_	_	_
27	by	_	_	IN	_	_	_	_	_
28	hypoxia	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	task	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	VEGF	_	_	NNP	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	counteract	_	_	VB	_	_	_	_	_
8	oxygen	_	_	NN	_	_	_	_	_
9	deficiency	_	_	NN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	inducing	_	_	VBG	_	_	_	_	_
12	vascular	_	_	JJ	_	_	_	_	_
13	network	_	_	NN	_	_	_	_	_
14	growth	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	spite	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	hypoxia	_	_	NN	_	_	_	_	_
7	may	_	_	MD	_	_	_	_	_
8	not	_	_	RB	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	only	_	_	JJ	_	_	_	_	_
12	trigger	_	_	NN	_	_	_	_	_
13	factor	_	_	NN	_	_	_	_	_
14	for	_	_	IN	_	_	_	_	_
15	angiogenesis	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	applies	_	_	VBZ	_	_	_	_	_
3	particularly	_	_	RB	_	_	_	_	_
4	to	_	_	TO	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	initial	_	_	JJ	_	_	_	_	_
7	stages	_	_	NNS	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	carcinogenesis	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	when	_	_	WRB	_	_	_	_	_
12	cell	_	_	NN	_	_	_	_	_
13	hypoxia	_	_	NN	_	_	_	_	_
14	is	_	_	VBZ	_	_	_	_	_
15	not	_	_	RB	_	_	_	_	_
16	yet	_	_	RB	_	_	_	_	_
17	severe	_	_	JJ	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Regulation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	VEGF	_	_	NNP	_	_	_	_	_
4	secretion	_	_	NN	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	takes	_	_	VBZ	_	_	_	_	_
7	place	_	_	NN	_	_	_	_	_
8	by	_	_	IN	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	mechanism	_	_	NN	_	_	_	_	_
11	independent	_	_	JJ	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	hypoxia	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	involving	_	_	VBG	_	_	_	_	_
16	dysregulated	_	_	JJ	_	_	_	_	_
17	activation	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	mitogenic	_	_	JJ	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	survival	_	_	JJ	_	_	_	_	_
22	pathways	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	applies	_	_	VBZ	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	phosphatidylinositol	_	_	NN	_	_	_	_	_
5	3-kinase	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	Ras/mitogen-activated	_	_	JJ	_	_	_	_	_
8	protein	_	_	NN	_	_	_	_	_
9	kinase	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	PD-L1/PD-1	_	_	NNP	_	_	_	_	_
3	axis	_	_	NN	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	have	_	_	VB	_	_	_	_	_
7	roles	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	regulating	_	_	VBG	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	level	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	VEGF	_	_	NN	_	_	_	_	_
14	mediating	_	_	VBG	_	_	_	_	_
15	angiogenesis	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	studies	_	_	NNS	_	_	_	_	_
3	conducted	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	Shin	_	_	NNP	_	_	_	_	_
6	et	_	_	FW	_	_	_	_	_
7	al.	_	_	FW	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	a	_	_	DT	_	_	_	_	_
10	positive	_	_	JJ	_	_	_	_	_
11	correlation	_	_	NN	_	_	_	_	_
12	between	_	_	IN	_	_	_	_	_
13	PDL1	_	_	NNP	_	_	_	_	_
14	levels	_	_	NNS	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	VEGF	_	_	NN	_	_	_	_	_
17	expression	_	_	NN	_	_	_	_	_
18	was	_	_	VBD	_	_	_	_	_
19	shown	_	_	VBN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	197	_	_	CD	_	_	_	_	_
22	patients	_	_	NNS	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	renal	_	_	JJ	_	_	_	_	_
25	cell	_	_	NN	_	_	_	_	_
26	carcinoma	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Similar	_	_	JJ	_	_	_	_	_
2	observations	_	_	NNS	_	_	_	_	_
3	were	_	_	VBD	_	_	_	_	_
4	noted	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	Song	_	_	NNP	_	_	_	_	_
7	et	_	_	FW	_	_	_	_	_
8	al.	_	_	FW	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	study	_	_	NN	_	_	_	_	_
3	was	_	_	VBD	_	_	_	_	_
4	conducted	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	64	_	_	CD	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	primary	_	_	JJ	_	_	_	_	_
10	glioma	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	Also	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	they	_	_	PRP	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	PD-L1	_	_	NN	_	_	_	_	_
7	expression	_	_	NN	_	_	_	_	_
8	levels	_	_	NNS	_	_	_	_	_
9	correlated	_	_	VBD	_	_	_	_	_
10	well	_	_	RB	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	VEGF	_	_	NNP	_	_	_	_	_
13	levels	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	not	_	_	RB	_	_	_	_	_
4	all	_	_	DT	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	agreed	_	_	VBN	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	this	_	_	DT	_	_	_	_	_
9	point	_	_	NN	_	_	_	_	_
10	.	_	_	.	_	_	_	_	_


1	Research	_	_	NN	_	_	_	_	_
2	by	_	_	IN	_	_	_	_	_
3	Joseph	_	_	NNP	_	_	_	_	_
4	et	_	_	FW	_	_	_	_	_
5	al.	_	_	FW	_	_	_	_	_
6	indicates	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	existence	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	negative	_	_	JJ	_	_	_	_	_
12	relationship	_	_	NN	_	_	_	_	_
13	between	_	_	IN	_	_	_	_	_
14	VEGF-related	_	_	JJ	_	_	_	_	_
15	genes	_	_	NNS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	activity	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	PD-L1/PD1	_	_	NNP	_	_	_	_	_
22	axis	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	thorough	_	_	JJ	_	_	_	_	_
3	understanding	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	nature	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	this	_	_	DT	_	_	_	_	_
9	relationship	_	_	NN	_	_	_	_	_
10	requires	_	_	VBZ	_	_	_	_	_
11	further	_	_	JJR	_	_	_	_	_
12	work	_	_	NN	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	EGF	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	another	_	_	DT	_	_	_	_	_
4	molecule	_	_	NN	_	_	_	_	_
5	with	_	_	IN	_	_	_	_	_
6	similar	_	_	JJ	_	_	_	_	_
7	effects	_	_	NNS	_	_	_	_	_
8	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	promotes	_	_	VBZ	_	_	_	_	_
3	tumor	_	_	NN	_	_	_	_	_
4	angiogenesis	_	_	NN	_	_	_	_	_
5	as	_	_	RB	_	_	_	_	_
6	well	_	_	RB	_	_	_	_	_
7	as	_	_	IN	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	increase	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	cell	_	_	NN	_	_	_	_	_
12	motility	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	invasiveness	_	_	NN	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	done	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	phosphorylating	_	_	VBG	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	EGFR	_	_	NN	_	_	_	_	_
8	receptor	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	activating	_	_	VBG	_	_	_	_	_
11	further	_	_	JJR	_	_	_	_	_
12	signaling	_	_	VBG	_	_	_	_	_
13	pathways	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	both	_	_	CC	_	_	_	_	_
7	EGFR	_	_	NNP	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	its	_	_	PRP$	_	_	_	_	_
10	mutated	_	_	VBN	_	_	_	_	_
11	form	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	EGFRvIII	_	_	NNP	_	_	_	_	_
14	promote	_	_	VBP	_	_	_	_	_
15	GBM	_	_	NNP	_	_	_	_	_
16	angiogenesis	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	allow	_	_	VB	_	_	_	_	_
3	vasculature	_	_	NN	_	_	_	_	_
4	growth	_	_	NN	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	tumor	_	_	NN	_	_	_	_	_
7	invasion	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	it	_	_	PRP	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	necessary	_	_	JJ	_	_	_	_	_
12	to	_	_	TO	_	_	_	_	_
13	reduce	_	_	VB	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	integrity	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	tumor	_	_	NN	_	_	_	_	_
19	microenvironment	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	pathophysiology	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	process	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	based	_	_	VBN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	EGFR	_	_	NNP	_	_	_	_	_
10	inducing	_	_	VBG	_	_	_	_	_
11	an	_	_	DT	_	_	_	_	_
12	increase	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	activity	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	some	_	_	DT	_	_	_	_	_
18	proteases	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	thereby	_	_	RB	_	_	_	_	_
21	causing	_	_	VBG	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	breakdown	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	collagen	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	fibronectin	_	_	NN	_	_	_	_	_
28	,	_	_	,	_	_	_	_	_
29	and	_	_	CC	_	_	_	_	_
30	other	_	_	JJ	_	_	_	_	_
31	basement	_	_	NN	_	_	_	_	_
32	membrane	_	_	NN	_	_	_	_	_
33	structures	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	result	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	loss	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	microenvironment	_	_	NN	_	_	_	_	_
8	integrity	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	increase	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	tumor	_	_	NN	_	_	_	_	_
14	cell	_	_	NN	_	_	_	_	_
15	invasion	_	_	NN	_	_	_	_	_
16	into	_	_	IN	_	_	_	_	_
17	surrounding	_	_	VBG	_	_	_	_	_
18	tissues	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	vessels	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	an	_	_	DT	_	_	_	_	_
24	increase	_	_	NN	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	angiogenesis	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	proteases	_	_	NNS	_	_	_	_	_
3	whose	_	_	WP$	_	_	_	_	_
4	activity	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	influenced	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	EGFR	_	_	NNP	_	_	_	_	_
9	include	_	_	VBP	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	among	_	_	IN	_	_	_	_	_
12	others	_	_	NNS	_	_	_	_	_
13	:	_	_	:	_	_	_	_	_


1	Serine	_	_	NNP	_	_	_	_	_
2	Proteases	_	_	NNPS	_	_	_	_	_


1	Matrix	_	_	NN	_	_	_	_	_
2	Metalloproteases	_	_	NNS	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	MMPs	_	_	NNP	_	_	_	_	_
5	)	_	_	-RRB-	_	_	_	_	_


1	Cysteine	_	_	NNP	_	_	_	_	_
2	Proteases	_	_	NNS	_	_	_	_	_
3	.	_	_	.	_	_	_	_	_


1	Serine	_	_	NNP	_	_	_	_	_
2	proteases	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	large	_	_	JJ	_	_	_	_	_
6	group	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	proteases	_	_	NNS	_	_	_	_	_
9	which	_	_	WDT	_	_	_	_	_
10	include	_	_	VBP	_	_	_	_	_
11	tissue	_	_	NN	_	_	_	_	_
12	plasminogen	_	_	NN	_	_	_	_	_
13	activator	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	tPA	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	urokinase	_	_	NN	_	_	_	_	_
19	plasminogen	_	_	NN	_	_	_	_	_
20	activator	_	_	NN	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	uPA	_	_	NN	_	_	_	_	_
23	)	_	_	-RRB-	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	its	_	_	PRP$	_	_	_	_	_
26	receptor	_	_	NN	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	uPAR	_	_	NN	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	Their	_	_	PRP$	_	_	_	_	_
2	activation	_	_	NN	_	_	_	_	_
3	affects	_	_	VBZ	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	degradation	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	extracellular	_	_	JJ	_	_	_	_	_
9	space	_	_	NN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	tumors	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	promoting	_	_	VBG	_	_	_	_	_
14	their	_	_	PRP$	_	_	_	_	_
15	invasiveness	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	PAI-1	_	_	NNP	_	_	_	_	_
9	molecule	_	_	NN	_	_	_	_	_
10	mediates	_	_	VBZ	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	regulation	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	uPA/uPAR	_	_	NN	_	_	_	_	_
16	pathway	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	astrocytoma	_	_	NN	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Its	_	_	PRP$	_	_	_	_	_
2	expression	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	promoted	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	an	_	_	DT	_	_	_	_	_
7	increase	_	_	NN	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	EGF	_	_	NNP	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	inflammatory	_	_	JJ	_	_	_	_	_
12	cytokines	_	_	NNS	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	results	_	_	VBZ	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	greater	_	_	JJR	_	_	_	_	_
5	uPA/uPAR	_	_	NN	_	_	_	_	_
6	activity	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	thus	_	_	RB	_	_	_	_	_
9	increasing	_	_	VBG	_	_	_	_	_
10	tumor	_	_	NN	_	_	_	_	_
11	invasiveness	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Upregulation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	uPA	_	_	NN	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	uPAR	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	achieved	_	_	VBN	_	_	_	_	_
9	through	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	expression	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	EGFR	_	_	NN	_	_	_	_	_
15	ligand	_	_	NN	_	_	_	_	_
16	transforming	_	_	VBG	_	_	_	_	_
17	growth	_	_	NN	_	_	_	_	_
18	factor	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	TGFα	_	_	NN	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Studies	_	_	NNS	_	_	_	_	_
2	confirmed	_	_	VBD	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	malignant	_	_	JJ	_	_	_	_	_
6	gliomas	_	_	NNS	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	both	_	_	CC	_	_	_	_	_
9	PAI-1	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	EGFR	_	_	NN	_	_	_	_	_
12	activity	_	_	NN	_	_	_	_	_
13	correlate	_	_	VBP	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	higher	_	_	JJR	_	_	_	_	_
16	tumor	_	_	NN	_	_	_	_	_
17	malignancy	_	_	NN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	worse	_	_	JJR	_	_	_	_	_
20	prognosis	_	_	NN	_	_	_	_	_
21	for	_	_	IN	_	_	_	_	_
22	patients	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	EGF	_	_	NNP	_	_	_	_	_
2	also	_	_	RB	_	_	_	_	_
3	has	_	_	VBZ	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	potential	_	_	JJ	_	_	_	_	_
6	impact	_	_	NN	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	another	_	_	DT	_	_	_	_	_
9	group	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	proteases	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	i.	_	_	FW	_	_	_	_	_
14	e.	_	_	FW	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	MMPs	_	_	NNP	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	large	_	_	JJ	_	_	_	_	_
5	group	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	enzymes	_	_	NNS	_	_	_	_	_
8	whose	_	_	WP$	_	_	_	_	_
9	effect	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	based	_	_	VBN	_	_	_	_	_
12	on	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	regulation	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	metabolism	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	cell	_	_	NN	_	_	_	_	_
19	morphogenesis	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Disruption	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	their	_	_	PRP$	_	_	_	_	_
4	function	_	_	NN	_	_	_	_	_
5	also	_	_	RB	_	_	_	_	_
6	affects	_	_	VBZ	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	loss	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	cell	_	_	NN	_	_	_	_	_
11	integrity	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	been	_	_	VBN	_	_	_	_	_
4	shown	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	activity	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	certain	_	_	JJ	_	_	_	_	_
10	matrix	_	_	NN	_	_	_	_	_
11	metalloproteases	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	such	_	_	JJ	_	_	_	_	_
14	as	_	_	IN	_	_	_	_	_
15	MMP-2	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	gelatinase	_	_	NN	_	_	_	_	_
18	A	_	_	NN	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	MMP-9	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	gelatinase	_	_	NN	_	_	_	_	_
24	B	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	MMP-14	_	_	NNP	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	matrix	_	_	NN	_	_	_	_	_
30	metalloproteinase	_	_	NN	_	_	_	_	_
31	14	_	_	CD	_	_	_	_	_
32	)	_	_	-RRB-	_	_	_	_	_
33	is	_	_	VBZ	_	_	_	_	_
34	related	_	_	VBN	_	_	_	_	_
35	to	_	_	TO	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	pathophysiology	_	_	NN	_	_	_	_	_
38	of	_	_	IN	_	_	_	_	_
39	high-grade	_	_	JJ	_	_	_	_	_
40	gliomas	_	_	NNS	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	correlates	_	_	VBZ	_	_	_	_	_
3	with	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	severity	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	tumor	_	_	NN	_	_	_	_	_
8	invasion	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	its	_	_	PRP$	_	_	_	_	_
11	degree	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	malignancy	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Another	_	_	DT	_	_	_	_	_
2	group	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	proteases	_	_	NNS	_	_	_	_	_
5	are	_	_	VBP	_	_	_	_	_
6	cysteine	_	_	NN	_	_	_	_	_
7	proteases	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	examples	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	cathepsins	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	include	_	_	VBP	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	among	_	_	IN	_	_	_	_	_
5	others	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	cathepsin	_	_	NN	_	_	_	_	_
8	B	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	involved	_	_	VBN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	degradation	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	tumor	_	_	NN	_	_	_	_	_
17	microenvironment	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	Its	_	_	PRP$	_	_	_	_	_
2	expression	_	_	NN	_	_	_	_	_
3	(	_	_	-LRB-	_	_	_	_	_
4	mRNA	_	_	NN	_	_	_	_	_
5	level	_	_	NN	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	has	_	_	VBZ	_	_	_	_	_
8	been	_	_	VBN	_	_	_	_	_
9	shown	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	correlate	_	_	VB	_	_	_	_	_
12	with	_	_	IN	_	_	_	_	_
13	EGFR	_	_	NNP	_	_	_	_	_
14	expression	_	_	NN	_	_	_	_	_
15	level	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	confirmed	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	its	_	_	PRP$	_	_	_	_	_
7	presence	_	_	NN	_	_	_	_	_
8	is	_	_	VBZ	_	_	_	_	_
9	increased	_	_	VBN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	gliomas	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	action	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	cathepsin	_	_	NN	_	_	_	_	_
5	B	_	_	NN	_	_	_	_	_
6	may	_	_	MD	_	_	_	_	_
7	be	_	_	VB	_	_	_	_	_
8	bidirectional	_	_	JJ	_	_	_	_	_
9	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	promotes	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	degradation	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	integrity	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	environment	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	tumor	_	_	NN	_	_	_	_	_
14	directly	_	_	RB	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	through	_	_	IN	_	_	_	_	_
17	intermediate	_	_	JJ	_	_	_	_	_
18	mediators	_	_	NNS	_	_	_	_	_
19	such	_	_	JJ	_	_	_	_	_
20	as	_	_	IN	_	_	_	_	_
21	uPA	_	_	NNP	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	MMPs	_	_	NNP	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	or	_	_	CC	_	_	_	_	_
26	plasmin	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_

